Tamiflu oseltamivir oral neuraminidase inhibitor regulatory update

The FDA granted marketing approval for the partners' Tamiflu to treat influenza illness in children one year and older who have been symptomatic for no more than two days. A suspension formulation of the product, which will be available to both pediatric patients and adults, is expected to be launched in mid-January 2001.

Separately, Japan granted marketing approval for Tamiflu to treat influenza A and B virus infection in adults. The product is marketed to treat influenza in 30 countries, including the U.S. and Canada. ...